Prostate specific antigen: Useful screening tool or potential liability?

Abstract

Background: The uncertainty regarding prostate specific antigen (PSA) screening for prostate cancer has not been alleviated, despite recent randomised controlled trials and position statements released by authoritative bodies. Objective: This article summarises authoritative position statements by representative bodies in Australia and describes legal considerations for a general practitioner when deciding whether to order PSA tests as a screening tool for prostate cancer. Discussion: Prostate specific antigen as a primary screening tool is generally not endorsed by most authoritative bodies in Australia, with the exception in some circumstances for men 55-69 years of age. Where asymptomatic..